We are live on ! Find out more
NCM

Nantahala Capital Management Portfolio holdings

AUM $2.72B
1-Year Est. Return 121.58%
This Fund
S&P 500
This Quarter Est. Return
+19.43%
1 Year Est. Return
+121.58%
3 Year Est. Return
+308.64%
5 Year Est. Return
+308.9%
10 Year Est. Return
+2,888.73%
AUM
$1.75B
AUM Growth
+$77.9M
Cap. Flow
-$78.7M
Cap. Flow %
-4.49%
Top 10 Hldgs %
55.92%
Holding
150
New
22
Increased
25
Reduced
39
Closed
26

Top Buys

Rank Stock Value
1
PTON icon
Peloton Interactive
PTON
+$15.1M
2
TRML
Tourmaline Bio
TRML
+$10.2M
3
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$6.91M
4
EHTH icon
eHealth
EHTH
+$6.1M
5
CONN
Conn's Inc.
CONN
+$6.03M

Top Sells

Rank Stock Value
1
ESTA icon
Establishment Labs
ESTA
+$20.3M
2
SLNO
Soleno Therapeutics
SLNO
+$20.2M
3
IWM icon
iShares Russell 2000 ETF
IWM
+$19.5M
4
LXFR icon
Luxfer Holdings
LXFR
+$10.1M
5
CYTK icon
Cytokinetics
CYTK
+$9.19M

Sector Composition

Rank Sector Weight
1 Healthcare 36.87%
2 Consumer Discretionary 8.07%
3 Financials 4.11%
4 Communication Services 3.43%
5 Technology 2.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
126
Cytokinetics
CYTK
$10.7B
– –
-110,017
Closed -$9.19M
DNTH icon
127
Dianthus Therapeutics
DNTH
$6.08B
– –
-328,433
Closed -$3.42M
EHTH icon
128
CALL
eHealth
EHTH
$39.1M
– –
-250,000
Closed -$2.18M
HGV icon
129
CALL
Hilton Grand Vacations
HGV
$3.36B
– –
-250,000
Closed -$10M
IDYA icon
130
IDEAYA Biosciences
IDYA
$3.57B
– –
-139,298
Closed -$4.96M
IMAX icon
131
CALL
IMAX
IMAX
$2.77B
– –
-250,000
Closed -$3.75M
IWM icon
132
iShares Russell 2000 ETF
IWM
$81.8B
– –
-97,969
Closed -$19.5M
JSPR icon
133
Jasper Therapeutics
JSPR
$29.8M
– –
-222,827
Closed -$1.76M
KROS icon
134
CALL
Keros Therapeutics
KROS
$210M
– –
-11,400
Closed -$453K
MLKN icon
135
MillerKnoll
MLKN
$1.63B
– –
-167,148
Closed -$4.46M
RFL icon
136
Rafael Holdings
RFL
$104M
– –
-73,695
Closed -$133K
RH icon
137
CALL
RH
RH
$3.46B
– –
-40,000
Closed -$11.7M
RNAC icon
138
Cartesian Therapeutics
RNAC
$257M
– –
-74,474
Closed -$1.54M
SNDX icon
139
CALL
Syndax Pharmaceuticals
SNDX
$1.8B
– –
-200,000
Closed -$4.32M
SPRY icon
140
ARS Pharmaceuticals
SPRY
$583M
– –
-1,596,504
Closed -$8.75M
SRTS icon
141
Sensus Healthcare
SRTS
$50.9M
– –
-176,750
Closed -$417K
TLPH icon
142
CALL
Talphera
TLPH
$76.3M
– –
-755,000
Closed -$555K
ZM icon
143
CALL
Zoom
ZM
$31.1B
– –
-100,000
Closed -$7.19M
LENZ
144
LENZ Therapeutics
LENZ
$163M
– –
-117,282
Closed -$2.15M
SCTL
145
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
– –
-1,214,706
Closed -$426K
AYX
146
DELISTED
Alteryx Inc
AYX
– –
-99,093
Closed -$4.67M
SRT
147
DELISTED
Startek Inc.
SRT
– –
-786,913
Closed -$3.47M
EAR
148
DELISTED
Eargo, Inc. Common Stock
EAR
– –
-495,582
Closed -$1.28M
2 3 4 5
6

Similar funds

TAM
Timucuan Asset Management Jacksonville, Florida $2.72B AUM 4.95% 1-Year Est. Return
XL
XN LP New York $2.72B AUM 46.67% 1-Year Est. Return
PA
Profund Advisors Bethesda, Maryland $2.72B AUM 47.27% 1-Year Est. Return
BCM
Bowie Capital Management Richardson, Texas $2.71B AUM 5.42% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return
HCM
Hollencrest Capital Management Newport Beach, California $2.7B AUM 23.62% 1-Year Est. Return
GC
Giverny Capital Montreal, Quebec, Canada $2.73B AUM 14.09% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

Nantahala Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Nantahala Capital Management held 150 positions worth $1.75B, up 4.7% from $1.67B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Nantahala Capital Management withdrew a net $78.7M in Q1 2024, closing 26 positions and reducing 39 holdings. Its most notable exit was iShares Russell 2000 ETF, an estimated $19.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 37% of assets, up from 35% a quarter earlier, followed by Consumer Discretionary and Financials.

Against the trend, Nantahala Capital Management opened a new position in Eagle Pharmaceuticals, Inc. worth $6.6M.

  • Nantahala Capital Management's largest Q1 2024 buy was Eagle Pharmaceuticals, Inc.: 1,258,762 shares worth $6.6M.
  • Nantahala Capital Management added most to Peloton Interactive in Q1 2024, an estimated $15.1M increase.
  • Nantahala Capital Management's biggest Q1 2024 reduction was Establishment Labs, cutting an estimated $20.3M.
  • Nantahala Capital Management fully exited iShares Russell 2000 ETF in Q1 2024, selling an estimated $19.5M.
  • Nantahala Capital Management's ten largest holdings make up 56% of its $1.75B portfolio in Q1 2024.
  • Nantahala Capital Management opened 22 new positions and closed 26 in Q1 2024.
  • Nantahala Capital Management's portfolio value rose 4.7% quarter-over-quarter to $1.75B.

Based on Nantahala Capital Management's 13F filing for Q1 2024, filed 15 May 2024.